Daraxonrasib in Previously Treated RAS‑Mutant Non‑Small‑Cell Lung Cancer — NEJM Clinical Trial Rep

Article citation and indexing

The article titled “Daraxonrasib for Previously Treated RAS‑Mutant Non‑Small‑Cell Lung Cancer” is indexed as a Clinical Trial in the New England Journal of Medicine (N Engl J Med). The PubMed record lists the publication date as 3 September 2026 (volume 395, pages 882–893). The PubMed identifier (PMID) is 42685317 and the DOI is 10.1056/NEJMoa2504059.

Authorship and institutional affiliations

The manuscript lists Kathryn C. Arbour as first author and includes a large collaborative author group. Contributors represent multiple academic cancer centers and clinical research sites across the United States as well as authors affiliated with Revolution Medicines. Reported institutional affiliations on the PubMed entry include, but are not limited to, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, NYU Langone Health, Dana‑Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Sarah Cannon Research Institute, Columbia University, Moffitt Cancer Center, Johns Hopkins, M.D. Anderson Cancer Center, and Revolution Medicines (Revolution Medicines appears among industry affiliations).

Publication identifiers and journal details

This trial report is published in a high‑impact, peer‑reviewed journal (N Engl J Med). The PubMed entry provides bibliographic details (issue, page numbers), the DOI (10.1056/NEJMoa2504059), and the PMID (42685317), which can be used to locate the full text and supplemental materials in the journal or via institutional access.

Clinical trial designation and context

On PubMed the article is categorized as a Clinical Trial. The title indicates the investigational agent is daraxonrasib and the target population is patients with previously treated RAS‑mutant non‑small‑cell lung cancer. That framing signals that the trial evaluated daraxonrasib in a population selected for RAS mutations and in the setting of prior systemic therapy.

What is and is not reported on the provided PubMed excerpt

What is reported in the provided PubMed excerpt:

• Article title, author list, and collaborating investigators.
• Extensive institutional affiliations spanning multiple U.S. academic centers and industry.
• Publication metadata (journal name, date, volume, page range, DOI, PMID).
• Classification as a Clinical Trial on PubMed.

What is NOT included in the provided PubMed excerpt (details not reported in the source):

• Any trial abstract text or structured summary (background, methods, results, conclusions) is absent from the excerpt supplied.
• Specific trial design elements: phase (I/II/III), randomization status, control arm information, blinding, sample size, and statistical plan are not reported in the excerpt.
• Eligibility criteria and baseline patient characteristics, including which RAS mutation subtypes were enrolled (for example, KRAS G12C or other variants), prior lines and types of therapy, or performance status distributions are not available in the excerpt.
• Efficacy outcomes such as objective response rate, progression‑free survival, overall survival, duration of response, or relevant subgroup analyses are not provided.
• Safety and tolerability data, including the frequency and severity of adverse events, dose modifications, or treatment discontinuations, are not present.
• Any authors’ interpretation, clinical recommendations, or guideline implications are not reported in the provided text.

Because these core clinical details are missing from the supplied PubMed excerpt, any interpretation of daraxonrasib’s efficacy, comparative value, or safety profile would require review of the full NEJM article and any published supplementary material.

Implications for clinicians and next steps to obtain full data

The PubMed entry confirms that a peer‑reviewed clinical‑trial report of daraxonrasib in previously treated RAS‑mutant NSCLC exists and provides bibliographic keys to retrieve it. For clinicians, guideline writers, and researchers seeking to assess the drug’s clinical utility, the essential next steps are:

• Retrieve and read the full NEJM article using the DOI (10.1056/NEJMoa2504059) or the PubMed record (PMID 42685317) to review the trial design, population, endpoints, efficacy outcomes, and safety profile.

• Consult supplementary appendices and trial protocols, if available, for detailed methodology, statistical analysis plans, subgroup definitions, and biomarker assay methods.

• Evaluate whether the enrolled RAS mutation subtypes match patient populations encountered in practice and whether prior therapies reflect current standard‑of‑care sequencing.

• Review any industry disclosures and conflict‑of‑interest statements given the involvement of Revolution Medicines among authors’ affiliations.

• If considering incorporation into practice or clinical trial design, await guideline statements or independent corroboration where applicable, and consider regulatory approvals and label information once available.

Summary

The provided PubMed excerpt documents a NEJM clinical‑trial publication of daraxonrasib in previously treated RAS‑mutant non‑small‑cell lung cancer and supplies full bibliographic identifiers and an extensive author and affiliation list. The excerpt does not include the trial abstract, methods, results, or conclusions; therefore, all clinical outcome and safety information must be obtained from the full journal article and supplementary materials before drawing practice‑level conclusions.